Coloplast (BRSE:020259063) - Stock Price, News & Analysis

020259063 Stock Overview

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details

020259063 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	2/6
Financial Health	3/6
Dividends	3/6

Rewards

Price-To-Earnings ratio (39.4x) is below the Medical Equipment industry average (48.5x)

Earnings are forecast to grow 10.15% per year

Risk Analysis

Shares are highly illiquid

Dividend of 2.29% is not well covered by earnings or cash flows

Has a high level of debt

Coloplast A/S Competitors

Alcon

SWX:ALC

CHF 37.2b

Ypsomed Holding

SWX:YPSN

CHF 5.0b

Sonova Holding

SWX:SOON

CHF 18.8b

Straumann Holding

SWX:STMN

CHF 17.7b

Price History & Performance

Summary of all time highs, changes and price drops for Coloplast
Historical stock prices
Current Share Price	DKK 109.67
52 Week High	DKK 143.26
52 Week Low	DKK 102.98
Beta	0.24
11 Month Change	0%
3 Month Change	n/a
1 Year Change	-4.64%
33 Year Change	-0.17%
5 Year Change	41.23%
Change since IPO	33.34%

Recent updates

Shareholder Returns

	020259063	CH Medical Equipment	CH Market
7D	0%	-5.9%	-1.8%
1Y	-4.6%	13.1%	6.1%

Return vs Industry: 020259063 underperformed the Swiss Medical Equipment industry which returned 4.1% over the past year.

Return vs Market: 020259063 underperformed the Swiss Market which returned -0.9% over the past year.

Price Volatility

Is 020259063's price volatile compared to industry and market?
020259063 volatility
020259063 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	3.9%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.5%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: 020259063 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 020259063's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1954	14,572	Kristian Villumsen	www.coloplast.com

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.

Coloplast A/S Fundamentals Summary

How do Coloplast's earnings and revenue compare to its market cap?
020259063 fundamental statistics
Market cap	CHF 24.53b
Earnings (TTM)	CHF 622.66m
Revenue (TTM)	CHF 2.99b

39.4x

P/E Ratio

8.2x

P/S Ratio

Is 020259063 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
020259063 income statement (TTM)
Revenue	DKK 22.58b
Cost of Revenue	DKK 7.05b
Gross Profit	DKK 15.53b
Other Expenses	DKK 10.82b
Earnings	DKK 4.71b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 03, 2023

Earnings per share (EPS)	22.17
Gross Margin	68.78%
Net Profit Margin	20.84%
Debt/Equity Ratio	217.1%

How did 020259063 perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

90%

Payout Ratio

020259063 Stock Overview

Rewards

Risk Analysis

Coloplast A/S Competitors

SWX:ALC

CHF 37.2b

SWX:YPSN

CHF 5.0b

SWX:SOON

CHF 18.8b

SWX:STMN

CHF 17.7b

Price History & Performance

Recent News & Updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Less than half of directors are independent

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

First quarter 2021 earnings released

Revenue beats expectations

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

Shareholder Returns

Price Volatility

About the Company

Coloplast A/S Fundamentals Summary

39.4x

8.2x

Earnings & Revenue

Dividends

2.3%

90%